Mysthera Therapeutics

Mysthera Therapeutics is a preclinical-stage biotechnology startup focused on developing first-in-class oral therapies to address significant unmet needs in autoimmune diseases. Our unique approach has the potential to transform patient lives across multiple disease settings, including glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. We are pioneering the development of PIM kinase inhibitors as a treatment for multilineage immune cell-driven autoimmune diseases.